Payment overview · 2025
General Payments
$476.10
25 reported records · 10 companies
Healthcare provider profile · identity verified
Thomas E Hawkey, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SUMTER, SC · NPI 1043292618
Verified facts
What the public records show
CMS Open Payments records show Thomas E Hawkey, D.O. received $476.10 in general payments during 2025 across 25 reported records.
Esperion Therapeutics, Inc. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Nexletol, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $90.72 | 19.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.98 | 16.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.36 | 15.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.01 | 11.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.43 | 7.7% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $33.40 | 7.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.06 | 6.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.66 | 6.9% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.81 | 4.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.67 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $476.10 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $90.72 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.98 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.36 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $54.01 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $33.40 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 174 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 154 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
181 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 38 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
154 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 712 | 204 |
| Meloxicam | Meloxicam | 486 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 385 | 115 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 370 | 117 |
| Fluticasone Propionate | Fluticasone Propionate | 336 | 131 |
| Losartan Potassium | Losartan Potassium | 336 | 90 |
| Montelukast Sodium | Montelukast Sodium | 303 | 80 |
| Metformin Hcl Er | Metformin Hcl | 297 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 72 |
| Furosemide | Furosemide | 244 | 78 |
| Gabapentin | Gabapentin | 215 | 59 |
| Potassium Chloride | Potassium Chloride | 185 | 55 |
| Farxiga | Dapagliflozin Propanediol | 181 | 39 |
| Ezetimibe | Ezetimibe | 180 | 48 |
| Tramadol Hcl | Tramadol Hcl | 179 | 60 |
| Jardiance | Empagliflozin | 174 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 171 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 50 |
| Omeprazole | Omeprazole | 163 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 154 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 41 |
| Azithromycin | Azithromycin | 139 | 97 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 27 |
| Enalapril Maleate | Enalapril Maleate | 129 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 31 |
| Simvastatin | Simvastatin | 126 | 34 |
| Allopurinol | Allopurinol | 124 | 33 |
| Ozempic | Semaglutide | 124 | 22 |
| Metformin Hcl | Metformin Hcl | 122 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 42 |
| Glipizide Er | Glipizide | 119 | 32 |
| Lisinopril | Lisinopril | 112 | 37 |
| Pregabalin | Pregabalin | 103 | 22 |
| Carvedilol | Carvedilol | 99 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 24 |
| Trazodone Hcl | Trazodone Hcl | 97 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 28 |
| Januvia | Sitagliptin Phosphate | 95 | 19 |
| Prednisone | Prednisone | 94 | 64 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 26 |
| Entresto | Sacubitril/Valsartan | 86 | 18 |
| Chlorthalidone | Chlorthalidone | 84 | 24 |
| Atenolol | Atenolol | 83 | 23 |
| Alprazolam | Alprazolam | 81 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 21 |
| Eliquis | Apixaban | 80 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 22 |
| Sertraline Hcl | Sertraline Hcl | 72 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 22 |
| Donepezil Hcl | Donepezil Hcl | 69 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 15 |
| Alendronate Sodium | Alendronate Sodium | 59 | 18 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 50 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 17 |
| Famotidine | Famotidine | 49 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 12 |
| Fluconazole | Fluconazole | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 12 |
| Ramipril | Ramipril | 44 | suppressed |
| Valsartan | Valsartan | 44 | 12 |
| Amoxicillin | Amoxicillin | 43 | 36 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 11 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 12 |
| Ondansetron Odt | Ondansetron | 41 | 18 |
| Nexletol | Bempedoic Acid | 40 | suppressed |
| Fenofibrate | Fenofibrate | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Glipizide | Glipizide | 36 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 14 |
| Febuxostat | Febuxostat | 30 | suppressed |
| Felodipine Er | Felodipine | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 23 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 12 |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 14 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $476.10 · 25 records | Esperion Therapeutics, Inc. | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, NEXLETOL, NUPLAZID, OTEZLA, REPATHA, TRELEGY ELLIPTA, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error